Kyuwon (Paul) Choi's questions to Vir Biotechnology Inc (VIR) leadership • Q1 2025
Question
Kyuwon (Paul) Choi inquired about the rationale behind the new triplet combination strategy involving a Virion asset, which is the subject of an EASL late-breaker. He also asked for an update on the enrollment timelines for the ECLIPSE-1 and ECLIPSE-2 studies.
Answer
Mark Eisner (Executive) clarified that the triplet study is conducted by Virion, not VIR, although VIR provided the assets for the trial. For VIR's own trials, he stated that the company aims to complete enrollment for ECLIPSE-1 by the end of 2024 to meet an estimated study completion date of late 2026. He also noted that ECLIPSE-2 has a shorter 24-week primary endpoint, and further guidance on its timing will be provided later.